A study in PNAS evaluates AI chatbots against human benchmarks, revealing that AI exhibits human-like behaviors and personality traits, with ChatGPT-4 closely mirroring human responses in strategic decision-making and personality assessments.
Gilead to snap up liver disease biotech CymaBay for $4.3B
Gilead is betting $4.3 billion on a biotech six months before the FDA is expected to make an approval decision on its rare liver disease